Table 3.
Distribution of nvAMD OCT lesion characteristics at weekly time points from baseline until week 4 post-injection with Ranibizumab.
| OCT lesion characteristics (n=48) | Baseline | Week 1 | Week 2 | Week 3 | Week 4 |
|---|---|---|---|---|---|
| Retinal Cysts | 32 (66.67%) | 15 (31.25%) | 10 (20.83%) | 12 (25%) | 16 (33.33%) |
| Subretinal Fluid | 26 (54.17%) | 16 (33.3%) | 13 (27.08%) | 11 (22.92%) | 16 (33.33%) |
| Pigment Epithelial Detachment | 27 (56.25%) | 18 (37.5%) | 13 (27.08%) | 12 (25%) | 13 (27.08%) |